» Articles » PMID: 27145016

Brain GABA Levels Across Psychiatric Disorders: A Systematic Literature Review and Meta-analysis of (1) H-MRS Studies

Overview
Journal Hum Brain Mapp
Publisher Wiley
Specialty Neurology
Date 2016 May 5
PMID 27145016
Citations 144
Authors
Affiliations
Soon will be listed here.
Abstract

The inhibitory gamma-aminobutyric acid (GABA) system is involved in the etiology of most psychiatric disorders, including schizophrenia, autism spectrum disorder (ASD) and major depressive disorder (MDD). It is therefore not surprising that proton magnetic resonance spectroscopy ((1) H-MRS) is increasingly used to investigate in vivo brain GABA levels. However, integration of the evidence for altered in vivo GABA levels across psychiatric disorders is lacking. We therefore systematically searched the clinical (1) H-MRS literature and performed a meta-analysis. A total of 40 studies (N = 1,591) in seven different psychiatric disorders were included in the meta-analysis: MDD (N = 437), schizophrenia (N = 517), ASD (N = 150), bipolar disorder (N = 129), panic disorder (N = 81), posttraumatic stress disorder (PTSD) (N = 104), and attention deficit/hyperactivity disorder (ADHD) (N = 173). Brain GABA levels were lower in ASD (standardized mean difference [SMD] = -0.74, P = 0.001) and in depressed MDD patients (SMD = -0.52, P = 0.005), but not in remitted MDD patients (SMD = -0.24, P = 0.310) compared with controls. In schizophrenia this finding did not reach statistical significance (SMD = -0.23, P = 0.089). No significant differences in GABA levels were found in bipolar disorder, panic disorder, PTSD, and ADHD compared with controls. In conclusion, this meta-analysis provided evidence for lower brain GABA levels in ASD and in depressed (but not remitted) MDD patients compared with healthy controls. Findings in schizophrenia were more equivocal. Even though future (1) H-MRS studies could greatly benefit from a longitudinal design and consensus on the preferred analytical approach, it is apparent that (1) H-MRS studies have great potential in advancing our understanding of the role of the GABA system in the pathogenesis of psychiatric disorders. Hum Brain Mapp 37:3337-3352, 2016. © 2016 Wiley Periodicals, Inc.

Citing Articles

Gamma-Aminobutyric Acid Action on Membrane and Electrical Properties of Synaptosomes and Model Lipid Bilayers.

Doltchinkova V, Vitkova V, Petkov O, Kitanova M, Stoyanova-Ivanova A, Lozanova S J Membr Biol. 2025; .

PMID: 39923215 DOI: 10.1007/s00232-025-00339-2.


The neuropsychological profile of SSADH deficiency, a neurotransmitter disorder of GABA metabolism.

Tokatly Latzer I, Hanson E, Bertoldi M, DiBacco M, Aygun D, Afacan O Mol Genet Metab. 2025; 144(3):109051.

PMID: 39919676 PMC: 11879317. DOI: 10.1016/j.ymgme.2025.109051.


Alterations in Striatal Architecture and Biochemical Markers' Levels During Postnatal Development in the Rat Model of an Attention Deficit/Hyperactivity Disorder (ADHD).

Bogdanska-Chomczyk E, Wojtacha P, Tsai M, Huang A, Kozlowska A Int J Mol Sci. 2025; 25(24.

PMID: 39769412 PMC: 11680085. DOI: 10.3390/ijms252413652.


Cerebellar contribution to emotion regulation and its association with medial frontal GABA level.

Oboshi Y, Iwabuchi T, Takata Y, Bunai T, Ouchi Y Soc Cogn Affect Neurosci. 2024; 20(1).

PMID: 39673407 PMC: 11776713. DOI: 10.1093/scan/nsae091.


Charting brain GABA and glutamate levels across psychiatric disorders by quantitative analysis of 121 H-MRS studies.

Zhang J, Toulopoulou T, Li Q, Niu L, Peng L, Dai H Psychol Med. 2024; :1-12.

PMID: 39564744 PMC: 11650199. DOI: 10.1017/S0033291724001673.


References
1.
Sanacora G, Fenton L, Fasula M, Rothman D, Levin Y, Krystal J . Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biol Psychiatry. 2005; 59(3):284-6. DOI: 10.1016/j.biopsych.2005.07.015. View

2.
Lewis D, Hashimoto T, Volk D . Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005; 6(4):312-24. DOI: 10.1038/nrn1648. View

3.
Bollmann S, Ghisleni C, Poil S, Martin E, Ball J, Eich-Hochli D . Developmental changes in gamma-aminobutyric acid levels in attention-deficit/hyperactivity disorder. Transl Psychiatry. 2015; 5:e589. PMC: 4490289. DOI: 10.1038/tp.2015.79. View

4.
Behar K, Rothman D, Petersen K, Hooten M, Delaney R, Petroff O . Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am J Psychiatry. 1999; 156(6):952-4. DOI: 10.1176/ajp.156.6.952. View

5.
Mori T, Mori K, Fujii E, Toda Y, Miyazaki M, Harada M . Evaluation of the GABAergic nervous system in autistic brain: (123)I-iomazenil SPECT study. Brain Dev. 2011; 34(8):648-54. DOI: 10.1016/j.braindev.2011.10.007. View